Company

Product

Description

Indication

Status

Affimed NV, of Heidelberg, Germany

AFM-24

Bispecific EGFR/CD16A innate cell engager

Cancer

Submitted IND for first trial of AFM-13 pre-mixed with cord blood-derived allogeneic NK cells in patients with relapsed/refractory CD30-positive lymphoid malignancies; registration-directed phase II on track to start this quarter

Algenex SL, of Madrid, Spain

Undisclosed

Vaccine using Baculovirus-based technology for production of recombinant biologics

Undisclosed

Partner submitted a dossier to the EMA for a recombinant VLP vaccine produced using Algenex' Crisbio technology

Ipsen Biopharmaceuticals Canada Inc., of Mississauga, Ontario, part of Ipsen SA

Cabometyx (cabozantinib)

Kinase inhibitor targeting VEGFR, MET and AXL pathways

Advanced renal cell carcinoma

Approved by Health Canada for first-line treatment in adults

Noven Pharmaceuticals Inc., of Miami, a wholly owned subsidiary of Hisamitsu Pharmaceutical Co. Inc.

Secuado (asenapine) transdermal system

Psychotropic agent delivered via transdermal patch

Schizophrenia

Approved by FDA for use in adults

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments